<DOC>
	<DOC>NCT01660035</DOC>
	<brief_summary>The purpose of the REVERSE Post Approval Study (PAS) is to confirm the benefit observed in the REVERSE and RAFT pivotal studies in "real-world" clinical practice.</brief_summary>
	<brief_title>The Product Surveillance Registry REVERSE Post Approval Study</brief_title>
	<detailed_description>The REVERSE PAS will estimate the 3-year survival probability of freedom from heart failure hospitalization and heart failure events in patients implanted with a Medtronic CRT-D device who meet the expanded indication criteria with a QRS duration ≤ 150 ms.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements Patient has or is intended to receive or be treated with a Medtronic CRTD who meets the expanded CRTD indication criteria with a QRS ≤ 150ms Patient within 30 days of implant Patient who is, or will be, inaccessible for followup Patient with exclusion criteria required by local law Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>